Inventiva, a clinical-stage biopharmaceutical company, announced the filing of its Half-Year Report for the six-month period ended June 30, 2024. The report was submitted to the French financial markets authority, Autorité des Marchés Financiers (AMF). The company focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and other diseases with unmet medical needs.
The company's condensed consolidated interim financial statements for the six-month period ended June 30, 2024, were prepared under the responsibility of the Board of Directors and approved by it on a going concern basis on October 14, 2024.
Lanifibranor: A Phase III Candidate for MASH/NASH
Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial named NATiV3. This trial is evaluating the efficacy and safety of lanifibranor in adult patients with MASH/NASH, a progressive chronic liver disease affecting a significant portion of the global population.
Pipeline and Strategic Focus
In addition to lanifibranor, Inventiva's pipeline includes odiparcil, a drug candidate for treating adult MPS VI patients. However, the company has suspended clinical efforts related to odiparcil to focus on lanifibranor's development. Inventiva is currently reviewing available options for the potential further development of odiparcil. Furthermore, Inventiva is in the process of selecting a candidate for its Hippo signaling pathway program, aiming to expand its therapeutic pipeline.
About Inventiva
Inventiva has a scientific team of approximately 90 people with expertise in biology, medicinal and computational chemistry, pharmacokinetics, pharmacology, and clinical development. The company owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.
